source
- Biohaven signs up to $795 million deal with SK Biopharma to license Kv7 platform and epilepsy assetBiohaven announced a licensing agreement with South Korean SK Biopharma centered on its Kv7 ion channel platform and lead epilepsy candidate opakalim. The deal could deliver up to $795 million, in…
- J&J’s Imaavy gains first-in-class label for warm autoimmune hemolytic anemiaJ&J announced that its monoclonal antibody Imaavy has received a label expansion in the United States. The expanded indication makes Imaavy the first therapy approved specifically for warm autoimm…